Peter A. Thompson
CIK: 0001357522
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (47 total)
- Jul 7, 2026SION
Sionna Therapeutics, Inc.
Sale(S)Indirect85.9K shares at avg. $44.86$3.9M - Jun 30, 2026SION
Sionna Therapeutics, Inc.
Sale(S)Indirect115.8K shares at avg. $45.50$5.3M - Jun 24, 2026SPRY
ARS Pharmaceuticals, Inc.
Award(A)DirectStock Option (right to buy)
30K shares- - Jun 17, 2026SION
Sionna Therapeutics, Inc.
Award(A)DirectNon-Qualified Stock Option (right to buy)
17.3K shares- - Jun 11, 2026CRVS
Corvus Pharmaceuticals, Inc.
Award(A)DirectStock Option (Right to Buy)
15K shares- - Jun 5, 2026EWTX
Edgewise Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
16.4K shares- - May 27, 2026SION
Sionna Therapeutics, Inc.
Sale(S)Indirect101 shares at avg. $44.49$4K - May 11, 2026SION
Sionna Therapeutics, Inc.
Sale(S)Indirect184.6K shares at avg. $46.22$8.5M - May 8, 2026SION
Sionna Therapeutics, Inc.
Sale(S)Indirect59.8K shares at avg. $44.58$2.7M - May 7, 2026SION
Sionna Therapeutics, Inc.
Sale(S)Indirect48.5K shares at avg. $44.61$2.2M - Apr 18, 2026SION
Sionna Therapeutics, Inc.
Sale(S)Indirect2.9K shares at avg. $44.52$131K - Apr 17, 2026SION
Sionna Therapeutics, Inc.
Sale(S)Indirect52.4K shares at avg. $44.68$2.3M - Apr 16, 2026SION
Sionna Therapeutics, Inc.
Sale(S)Indirect226.9K shares at avg. $45.34$10.3M - Apr 15, 2026SION
Sionna Therapeutics, Inc.
Sale(S)Indirect235.9K shares at avg. $44.64$10.5M - Apr 14, 2026SION
Sionna Therapeutics, Inc.
Sale(S)Indirect47.8K shares at avg. $44.51$2.1M - Feb 3, 2026SION
Sionna Therapeutics, Inc.
Sale(S)Indirect29.1K shares at avg. $44.58$1.3M - Feb 2, 2026SION
Sionna Therapeutics, Inc.
Sale(S)Indirect1.9K shares at avg. $44.57$84K - Jan 28, 2026CRVS
Corvus Pharmaceuticals, Inc.
Exercise(M)Direct15K shares at avg. $0.96$14K - Jan 28, 2026CRVS
Corvus Pharmaceuticals, Inc.
Exercise(M)Direct15K shares at avg. $2.74$41K - Jan 28, 2026CRVS
Corvus Pharmaceuticals, Inc.
Exercise(M)Direct15K shares at avg. $2.60$39K - Jan 28, 2026CRVS
Corvus Pharmaceuticals, Inc.
Exercise(M)Direct15K shares at avg. $0.99$15K - Jan 28, 2026CRVS
Corvus Pharmaceuticals, Inc.
Exercise(M)Direct15K shares at avg. $2.49$37K - Jan 28, 2026CRVS
Corvus Pharmaceuticals, Inc.
Exercise(M)Direct15K shares at avg. $2.12$32K - Jan 28, 2026CRVS
Corvus Pharmaceuticals, Inc.
Exercise(M)Direct15K shares at avg. $1.64$25K - Jan 28, 2026CRVS
Corvus Pharmaceuticals, Inc.
Exercise(M)Direct30K shares at avg. $15.00$450K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jul 7, 2026 |  SION Sionna Therapeutics, Inc. | Sale(S) | 85,918 | $44.86 | $3,854,281 | Indirect |
| Jun 30, 2026 | SION Sionna Therapeutics, Inc. | Sale(S) | 115,844 | $45.50 | $5,270,902 | Indirect |
| Jun 24, 2026 |  SPRY ARS Pharmaceuticals, Inc. | Award(A) Stock Option (right to buy) | 30,000 | - | - | Direct |
| Jun 17, 2026 | SION Sionna Therapeutics, Inc. | Award(A) Non-Qualified Stock Option (right to buy) | 17,340 | - | - | Direct |
| Jun 11, 2026 |  CRVS Corvus Pharmaceuticals, Inc. | Award(A) Stock Option (Right to Buy) | 15,000 | - | - | Direct |
| Jun 5, 2026 |  EWTX Edgewise Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 16,377 | - | - | Direct |
| May 27, 2026 | SION Sionna Therapeutics, Inc. | Sale(S) | 101 | $44.49 | $4,493 | Indirect |
| May 11, 2026 | SION Sionna Therapeutics, Inc. | Sale(S) | 184,639 | $46.22 | $8,534,015 | Indirect |
| May 8, 2026 | SION Sionna Therapeutics, Inc. | Sale(S) | 59,767 | $44.58 | $2,664,413 | Indirect |
| May 7, 2026 | SION Sionna Therapeutics, Inc. | Sale(S) | 48,546 | $44.61 | $2,165,637 | Indirect |
| Apr 18, 2026 | SION Sionna Therapeutics, Inc. | Sale(S) | 2,948 | $44.52 | $131,245 | Indirect |
| Apr 17, 2026 | SION Sionna Therapeutics, Inc. | Sale(S) | 52,397 | $44.68 | $2,341,098 | Indirect |
| Apr 16, 2026 | SION Sionna Therapeutics, Inc. | Sale(S) | 226,906 | $45.34 | $10,287,918 | Indirect |
| Apr 15, 2026 | SION Sionna Therapeutics, Inc. | Sale(S) | 235,863 | $44.64 | $10,528,924 | Indirect |
| Apr 14, 2026 | SION Sionna Therapeutics, Inc. | Sale(S) | 47,814 | $44.51 | $2,128,201 | Indirect |
| Feb 3, 2026 | SION Sionna Therapeutics, Inc. | Sale(S) | 29,063 | $44.58 | $1,295,629 | Indirect |
| Feb 2, 2026 | SION Sionna Therapeutics, Inc. | Sale(S) | 1,890 | $44.57 | $84,237 | Indirect |
| Jan 28, 2026 | CRVS Corvus Pharmaceuticals, Inc. | Exercise(M) | 15,000 | $0.96 | $14,475 | Direct |
| Jan 28, 2026 | CRVS Corvus Pharmaceuticals, Inc. | Exercise(M) | 15,000 | $2.74 | $41,100 | Direct |
| Jan 28, 2026 | CRVS Corvus Pharmaceuticals, Inc. | Exercise(M) | 15,000 | $2.60 | $39,000 | Direct |
| Jan 28, 2026 | CRVS Corvus Pharmaceuticals, Inc. | Exercise(M) | 15,000 | $0.99 | $14,849 | Direct |
| Jan 28, 2026 | CRVS Corvus Pharmaceuticals, Inc. | Exercise(M) | 15,000 | $2.49 | $37,350 | Direct |
| Jan 28, 2026 | CRVS Corvus Pharmaceuticals, Inc. | Exercise(M) | 15,000 | $2.12 | $31,800 | Direct |
| Jan 28, 2026 | CRVS Corvus Pharmaceuticals, Inc. | Exercise(M) | 15,000 | $1.64 | $24,600 | Direct |
| Jan 28, 2026 | CRVS Corvus Pharmaceuticals, Inc. | Exercise(M) | 30,000 | $15.00 | $450,000 | Direct |
1-25 of 47 transactions
About Thompson Peter A.
Thompson Peter A. (SEC CIK 0001357522) files insider reports with the SEC as Director of Aspen Neuroscience, Inc. (ASPE), Director of Sionna Therapeutics, Inc. (SION) and Director of ARS Pharmaceuticals, Inc. (SPRY). Signal8 also holds filings tied to 2 other companies.
Signal8 holds 24 ownership filings by Thompson Peter A. (2 Form 3, 22 Form 4), filed between Feb 6, 2025 and Oct 29, 2026. Those filings report 47 transactions, from Feb 10, 2025 to Jul 7, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Thompson Peter A.'s filings is in SAN DIEGO, CA.
Recent filings by Thompson Peter A.
- Jul 7, 2026: Open-market sale of SION shares (Form 4, code S).
- Jun 30, 2026: Open-market sale of SION shares (Form 4, code S).
- Jun 24, 2026: Grant or award of SPRY derivative securities (Form 4, code A).
- Jun 17, 2026: Grant or award of SION derivative securities (Form 4, code A).
- Jun 11, 2026: Grant or award of CRVS derivative securities (Form 4, code A).
Other insiders filing for Aspen Neuroscience, Inc. (ASPE)
- ARCH Venture Fund X, L.P., 10% Owner
- ARCH Venture Partners XIV, L.P., 10% Owner
- Spaventa Andrew, Director
- Hasnain Faheem, Executive Chair
- ORBIMED ADVISORS LLC, Director
- Boerneke Jeffrey Lee, General Counsel and Secretary